Literature DB >> 31191862

New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators.

Chamitha Weeramange1, Ashabha Lansakara1, Johnathan Dallman1, Thi Nguyen1, Wasundara Hulangamuwa1, Ryan J Rafferty1.   

Abstract

6-Thiopurine (6TP) is a potent cytotoxic agent that is a clinically prescribed anti-metabolite employed in the treatment of numerous blood cancers since 1952. However, its reported severe toxicities limit its general usage in the clinic. We previously have undertaken investigations into identifying the mode of toxicity for 6TP, and have found that the oxidative metabolites of 6TP, specifically 6-thiouric acid (6TU), is responsible for the in vitro inhibition of UDP-glucose dehydrogenase (UDPGDH) in a UV-vis method. In this method, inhibition was quantified through the quantification of NADH production, however, purines absorb at the same wavelength and thereby can interfere with the NADH detection. Herein, we report a HPLC method that allows for direct quantification of UDP-glucuronic acid, product from UDPGDH, for the assessment of inhibition towards UDPGDH with no interference from purines. In this method it was revealed that 6TP possesses a greater inhibitory properties than previously observed; 111 vs. 288 μM. Building upon the data collected from a previously performed rat hepatocyte study, which correlated our in vitro to in vivo inhibition theories about UDPGDH, we have developed a bio-mimic in vitro assay to aid in the inhibitory assessment of 6TP and analogs. In our efforts to expand the use of 6TP, and analogs constructed, our laboratory has undertaken a screening campaign to identify small molecule potentiators that work in synergy with 6TP in other types of cancers. Three chalcone-based compounds have been discovered through our total synthesis campaign of uvaretin, and it has been found that 11c has strong synergism with 6TP in the pancreatic cancer cell line MIA PaCa-2. Through the work presented herein, we reveal new methods to assess toxicity of 6TP and future analogs and new small molecules that work in synergy to expand the therapeutic applications of this neglected cytotoxic agent.

Entities:  

Year:  2019        PMID: 31191862      PMCID: PMC6533796          DOI: 10.1039/c9md00010k

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  27 in total

Review 1.  Management of Crohn's disease.

Authors:  D S Rampton
Journal:  BMJ       Date:  1999-12-04

Review 2.  Therapeutic trials in childhood ALL: what's their future?

Authors:  O B Eden
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

3.  In vitro metabolism of 6-mercaptopurine by human liver cytosol.

Authors:  K Rowland; L Lennard; J S Lilleyman
Journal:  Xenobiotica       Date:  1999-06       Impact factor: 1.908

4.  A clinical study of 6-mercaptopurine.

Authors:  P C GAFFNEY; W M COOPER
Journal:  Ann N Y Acad Sci       Date:  1954-12-06       Impact factor: 5.691

5.  Chemical suppression of the immune response.

Authors:  G H HITCHINGS; G B ELION
Journal:  Pharmacol Rev       Date:  1963-06       Impact factor: 25.468

Review 6.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

Authors:  Richard B Gearry; Murray L Barclay
Journal:  J Gastroenterol Hepatol       Date:  2005-08       Impact factor: 4.029

8.  Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine.

Authors:  J A Nelson; J W Carpenter; L M Rose; D J Adamson
Journal:  Cancer Res       Date:  1975-10       Impact factor: 12.701

9.  De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.

Authors:  Thierry Dervieux; Timothy L Brenner; Yuen Y Hon; Yinmei Zhou; Michael L Hancock; John T Sandlund; Gaston K Rivera; Raul C Ribeiro; James M Boyett; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  Characterization of human UDP-glucose dehydrogenase. CYS-276 is required for the second of two successive oxidations.

Authors:  Brandi J Sommer; Joseph J Barycki; Melanie A Simpson
Journal:  J Biol Chem       Date:  2004-03-24       Impact factor: 5.157

View more
  1 in total

1.  Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care.

Authors:  Zhe Zhou
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.